WCLC 2025 - Posters & ePosters-EP.07.55 Adjuvant Sunvozertinib for Early-Stage NSCLC Patients With EGFR Exon 20 Insertion Mutation: A Case Series

Pdf Summary

This case series retrospectively evaluated the efficacy and safety of sunvozertinib as adjuvant therapy in three early-stage non-small cell lung cancer (NSCLC) patients harboring EGFR exon 20 insertion (exon20ins) mutations. Patients, aged 55-72 years, had poorly differentiated lung adenocarcinoma at pathological stages IA1, IA2, and IIB. All underwent complete tumor resection followed by six months of daily oral sunvozertinib (150 mg). At data cutoff, none experienced disease recurrence, with the longest disease-free survival (DFS) reaching 17 months, surpassing the critical first-year recurrence peak commonly seen post-surgery in NSCLC. Mild toxicities occurred, including grade 1 oral mucositis and rash in two patients, with no new safety concerns detected.<br /><br />EGFR exon20ins mutations are associated with aggressive disease and earlier recurrence, making effective adjuvant treatment crucial. Sunvozertinib, a potent, selective EGFR tyrosine kinase inhibitor approved in China for advanced NSCLC with this mutation, demonstrated promising efficacy and tolerability in this early-stage setting. Molecular profiling revealed additional concurrent mutations (e.g., TP53, PTEN) among patients, but these did not affect treatment outcomes significantly.<br /><br />This initial real-world evidence suggests that sunvozertinib can effectively reduce recurrence risk post-surgery in early-stage NSCLC patients with EGFR exon20ins mutations, successfully bridging patients through the high-risk one-year period. Despite the small sample size, findings support further prospective studies to validate sunvozertinib’s role as adjuvant therapy in this population.<br /><br />In conclusion, adjuvant sunvozertinib shows sustained disease control and manageable side effects, offering a promising therapeutic option for NSCLC patients harboring EGFR exon20ins mutations following surgical resection. Future larger trials are warranted to confirm these preliminary benefits.

Asset Subtitle

Xiaohan Chen

Meta Tag

Speaker Xiaohan Chen

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

sunvozertinib

adjuvant therapy

early-stage non-small cell lung cancer

NSCLC

EGFR exon 20 insertion mutation

disease-free survival

tumor resection

tyrosine kinase inhibitor

treatment safety

molecular profiling